FFO
DYN icon

Fortitude Family Office’s Dyne Therapeutics DYN Stock Holding History

Fortitude Family Office’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.09K Buy
184
+159
+636% +$2.96K ﹤0.01% 1177
2026
Q1 		$453 Buy
+25
New +$431 ﹤0.01% 1765

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fortitude Family Office's DYN Position: Q2 2026 in Review

Fortitude Family Office increased its Dyne Therapeutics (DYN) stake by 636% in Q2 2026, buying an estimated $2.96K and bringing the position to 184 shares worth $4.09K. The position accounts for ﹤0.01% of the portfolio, ranked #1177.

Fortitude Family Office first reported a position in DYN in Q1 2026 and has held it in 2 quarters since. 245 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • Fortitude Family Office held 184 shares of Dyne Therapeutics worth $4.09K as of Q2 2026.
  • Fortitude Family Office bought 159 Dyne Therapeutics shares in Q2 2026, an estimated $2.96K.
  • Dyne Therapeutics made up ﹤0.01% of Fortitude Family Office's portfolio in Q2 2026, its #1177 holding.
  • Fortitude Family Office first reported a position in Dyne Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 245 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on Fortitude Family Office's 13F filing for Q2 2026, filed 20 Jul 2026.